(Q34619377)

3 August 2017

1 reference

title

Is severe liver disease a common outcome for people with chronic hepatitis C? (English)

1 reference

3 August 2017

1 reference

1 reference

4

John M Kaldor

1 reference

3 August 2017

1

Gregory J Dore

1 reference

3 August 2017

Anthony J Freeman

2

1 reference

PubMed ID

11982723

3 August 2017

Matthew Law

series ordinal

3

1 reference

3 August 2017

1 April 2002

1 reference

Journal of Gastroenterology and Hepatology

3 August 2017

1 reference

3 August 2017

17

1 reference

3 August 2017

423-430

1 reference

3 August 2017

4

1 reference

Persistent hepatitis C viremia after acute self-limiting posttransfusion hepatitis C.

3 August 2017

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02730.X

Different clinical behaviors of acute hepatitis C virus infection are associated with different vigor of the anti-viral cell-mediated immune response

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02730.X

Assessment of long-term outcomes of hepatitis C virus infection in a cohort of patients with acute hepatitis in 1971-1975: results of a pilot study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02730.X

Persistence of viremia and the importance of long-term follow-up after acute hepatitis C infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02730.X

Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02730.X

Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. The Consensus Interferon Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02730.X

Estimating progression to cirrhosis in chronic hepatitis C virus infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02730.X

Long-term mortality after transfusion-associated non-A, non-B hepatitis. The National Heart, Lung, and Blood Institute Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02730.X

Late seroconversion and high chronicity rate of hepatitis C virus infection in patients with hematologic disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02730.X

Non-A, non-B post-transfusion hepatitis. Looking back in the second decade

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02730.X

Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: A National Heart, Lung, and Blood Institute collaborative study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02730.X

Long-term persistence of hepatitis C virus antibodies in a single source outbreak

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02730.X

Clinical outcomes after hepatitis C infection from contaminated anti-D immune globulin. Irish Hepatology Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02730.X

Estimates of the cost-effectiveness of a single course of interferon-alpha 2b in patients with histologically mild chronic hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02730.X

Pretreatment evaluation of chronic hepatitis C: risks, benefits, and costs

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02730.X

Watchful waiting with periodic liver biopsy versus immediate empirical therapy for histologically mild chronic hepatitis C. A cost-effectiveness analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02730.X

Modeling the impact of interferon alfa treatment on liver fibrosis progression in chronic hepatitis C: a dynamic view. The Multivirc Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02730.X

Rates and risk factors of liver fibrosis progression in patients with chronic hepatitis c.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02730.X

Morbidity and mortality in compensated cirrhosis type C: a retrospective follow-up study of 384 patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02730.X

Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: a prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02730.X

The long-term outcomes of patients with compensated hepatitis C virus-related cirrhosis and history of parenteral exposure in the United States

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02730.X

Determinants of outcome of compensated hepatitis C virus-related cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02730.X

Which patients with hepatitis C develop liver complications?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02730.X

Persistence of viremia in patients with type-C chronic hepatitis during long-term follow-up

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02730.X

Modelling the hepatitis C virus epidemic in Australia. Hepatitis C Virus Projections Working Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02730.X

Epidemiology of hepatitis C: geographic differences and temporal trends

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02730.X

Influence of human immunodeficiency virus type 1 infection on the natural course of chronic parenterally acquired hepatitis C.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02730.X

Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02730.X

The progression of HCV-associated liver disease in a cohort of haemophilic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02730.X

Concurrent hepatitis B and C virus infection and risk of hepatocellular carcinoma in cirrhosis. A prospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02730.X

Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02730.X

Epidemiological factors affecting the severity of hepatitis C virus-related liver disease: a French survey of 6,664 patients. The Study Group for the Prevalence and the Epidemiology of Hepatitis C Virus

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02730.X

Risk factors for cirrhosis in patients with chronic hepatitis C virus infection: results of a case-control study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02730.X

Impact of alcohol on the histological and clinical progression of hepatitis C infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02730.X

Clinical course and risk factors of hepatitis C virus related liver disease in the general population: report from the Dionysos study

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02730.X

Role of alcohol in the progression of liver disease caused by hepatitis C virus infection

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02730.X

Prognosis of chronic hepatitis C: results of a large, prospective cohort study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02730.X

Lack of association between type of hepatitis C virus, serum load and severity of liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02730.X

Lack of correlation between hepatitis C virus genotypes and clinical course of hepatitis C virus-related cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02730.X

Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (I

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02730.X

Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02730.X

Slow progression rate of fibrosis in hepatitis C virus patients with persistently normal alanine transaminase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02730.X

Prospective study on anti-hepatitis C virus-positive patients with persistently normal serum alanine transaminase with or without detectable serum hepatitis C virus RNA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1440-1746.2002.02730.X

10.1046/J.1440-1746.2002.02730.X

21 January 2018

Identifiers

DOI

1 reference

3 August 2017

1 reference

PubMed ID

11982723